Literature DB >> 16685015

Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.

Tomohiro Handa1, Sonoko Nagai, Shinji Miki, Yasutaka Fushimi, Kosuke Ohta, Michiaki Mishima, Takateru Izumi.   

Abstract

OBJECTIVE: To investigate the frequency of pulmonary hypertension (PH) and clinical parameters associated with PH in sarcoidosis patients.
METHODS: A prospective, observational study was performed on 246 consecutive Japanese sarcoidosis patients followed up at the outpatient sarcoidosis clinic in the Central Clinic of Kyoto. The patients were evaluated for PH by Doppler echocardiography. Among these patients, 192 underwent pulmonary function tests. In addition, high-resolution CT of the lung was evaluated for the presence of lymph node enlargement, lung opacity, and thickening of bronchovascular bundles in 122 patients. PH was defined as estimated systolic pulmonary artery pressure (sPAP) > or = 40 mm Hg. The frequency of PH was evaluated, and clinical parameters were compared between patients with PH and those without PH.
RESULTS: Among 212 patients who were successfully evaluated for sPAP, 12 patients (5.7%) had PH. Patients with PH had the following clinical characteristics: advanced chest radiographic stage, decreased oxygen saturation, predominantly male gender, and decreased percentage of predicted vital capacity, percentage of predicted FVC, percentage of predicted FEV1, percentage of predicted functional residual capacity, and percentage of predicted total lung capacity (%TLC). Multivariate logistic regression analysis showed that decreased %TLC was independently associated with PH. There was a weak negative correlation between sPAP and %TLC (p < 0.05).
CONCLUSIONS: The frequency of PH in Japanese sarcoidosis patients was 5.7% evaluated with Doppler echocardiography. Decreased lung volume increases the risk of PH developing in patients with sarcoidosis.

Entities:  

Mesh:

Year:  2006        PMID: 16685015     DOI: 10.1378/chest.129.5.1246

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  47 in total

Review 1.  Imaging of Sarcoidosis.

Authors:  Mario Silva; Hilario Nunes; Dominique Valeyre; Nicola Sverzellati
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 2.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 3.  Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature.

Authors:  Alice Rossi; Maurizio Zompatori; Patrick Tchouante Tchouanhou; Michele Amadori; Massimiliano Palazzini; Elisa Conficoni; Nazzareno Galiè; Venerino Poletti; Giampaolo Gavelli
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

Review 4.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

5.  Tadalafil therapy for sarcoidosis-associated pulmonary hypertension.

Authors:  H J Ford; R P Baughman; R Aris; P Engel; J F Donohue
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

6.  Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis.

Authors:  Sunit Singla; Tong Zhou; Kamran Javaid; Taimur Abbasi; Nancy Casanova; Wei Zhang; Shwu-Fan Ma; Michael S Wade; Imre Noth; Nadera J Sweiss; Joe G N Garcia; Roberto F Machado
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

7.  18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis: Right ventricular uptake is associated with pathological uptake in mediastinal lymph nodes.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2018-05-02       Impact factor: 5.952

8.  Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.

Authors:  Aggeliki Rapti; Vasileios Kouranos; Elias Gialafos; Konstantina Aggeli; John Moyssakis; Anastasios Kallianos; Charalampos Kostopoulos; Ourania Anagnostopoulou; Petros P Sfikakis; Athol U Wells; George E Tzelepis
Journal:  Lung       Date:  2012-12-11       Impact factor: 2.584

9.  Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.

Authors:  Esam H Alhamad; Majdy M Idrees; Mohammed O Alanezi; Ahmad A Alboukai; Shaffi Ahmad Shaik
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

Review 10.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.